Clinical trial
Clinical trials are experiments or observations done in clinical research. Such prospective biomedical or behavioral research studies on human participants are designed to answer specific questions about biomedical or behavioral interventions, including new treatments and known interventions that warrant further study and comparison. Clinical trials generate data on efficacy, they are conducted only after they have received health authority/ethics committee approval in the country where approval of the therapy is sought. These authorities are responsible for vetting the risk/benefit ratio of the trial – their approval does not mean that the therapy is'safe' or effective, only that the trial may be conducted. Depending on product type and development stage, investigators enroll volunteers or patients into small pilot studies, subsequently conduct progressively larger scale comparative studies. Clinical trials can vary in size and cost, they can involve a single research center or multiple centers, in one country or in multiple countries.
Clinical study design aims to ensure the scientific reproducibility of the results. Costs for clinical trials can range into the billions of dollars per approved drug; the sponsor may be a governmental organization or a pharmaceutical, biotechnology or medical device company. Certain functions necessary to the trial, such as monitoring and lab work, may be managed by an outsourced partner, such as a contract research organization or a central laboratory. Only 10 percent of all drugs started in human clinical trials become an approved drug; some clinical trials involve healthy subjects with no pre-existing medical conditions. Other clinical trials pertain to patients with specific health conditions who are willing to try an experimental treatment; when participants are healthy volunteers who receive financial incentives, the goals are different than when the participants are sick. During dosing periods, study subjects remain under supervision for one to 40 nights. Pilot experiments are conducted to gain insights for design of the clinical trial to follow.
There are two goals to testing medical treatments: to learn whether they work well enough, called "efficacy" or "effectiveness". Neither is an absolute criterion; the benefits must outweigh the risks. For example, many drugs to treat cancer have severe side effects that would not be acceptable for an over-the-counter pain medication, yet the cancer drugs have been approved since they are used under a physician's care, are used for a life-threatening condition. In the US, the elderly constitute 14 % of the population. People over 55 are excluded from trials because their greater health issues and drug use complicate data interpretation, because they have different physiological capacity than younger people. Children and people with unrelated medical conditions are frequently excluded. Pregnant women are excluded due to potential risks to the fetus; the sponsor designs the trial in coordination with a panel of expert clinical investigators, including what alternative or existing treatments to compare to the new drug and what type of patients might benefit.
If the sponsor cannot obtain enough test subjects at one location investigators at other locations are recruited to join the study. During the trial, investigators recruit subjects with the predetermined characteristics, administer the treatment and collect data on the subjects' health for a defined time period. Data include measurements such as vital signs, concentration of the study drug in the blood or tissues, changes to symptoms, whether improvement or worsening of the condition targeted by the study drug occurs; the researchers send the data to the trial sponsor, who analyzes the pooled data using statistical tests. Examples of clinical trial goals include assessing the safety and relative effectiveness of a medication or device: On a specific kind of patient, for example, a patient, diagnosed with Alzheimer's disease At varying dosages, for example, a 10 milligram dose instead of a 5 milligram dose For a new indication Evaluation for improved efficacy in treating a patient's condition as compared to the standard therapy for that condition Evaluation of the study drug or device relative to two or more approved/common interventions for that condition, for example, device A versus device B, or therapy A versus therapy B)While most clinical trials test one alternative to the novel intervention, some expand to three or four and may include a placebo.
Except for small, single-location trials, the design and objectives are specified in a document called a clinical trial protocol. The protocol is the trial's "operating manual" and ensures that all researchers perform the trial in the same way on similar subjects and that the data is comparable across all subjects; as a trial is designed to test hypotheses and rigorously monitor and assess outcomes, it can be seen as an application of the scientific method the experimental step. The most common clinical trials evaluate new pharmaceutical products, medical devices, psychological therapies, or other interventions. Clinical trials may be required before a national regulatory authority approves marketing of the innovation. To drugs, manufacturers of medical devices in the United States are required to conduct clinical trials for premarket appr
Hallucinogen
A hallucinogen is a psychoactive agent which can cause hallucinations, perceptual anomalies, other substantial subjective changes in thoughts and consciousness. The common types of hallucinogens are psychedelics and deliriants. Although hallucinations are a common symptom of amphetamine psychosis, amphetamines are not considered hallucinogens, as they are not a primary effect of the drugs themselves. While hallucinations can occur when abusing stimulants, the nature of stimulant psychosis is not unlike delirium. A debate persists on criteria which would differentiate a substance which is'psychedelic' from one'hallucinogenic'. Sir Thomas Browne in 1646 coined the term'hallucination' from the Latin word "alucinari" meaning "to wander in the mind"; the term'psychedelic' is derived from the Ancient Greek words psychē and dēloun, or "mind-revealing".'A hallucinogen' and'a psychedelic' may refer to the same substance.'Hallucinations' and'psychedelia' may both refer to the same aspects of subjective experience in a given instance.
The term psychedelia carries an added reference to psychedelic substance culture, and'psychedelics' are considered by many to be the'traditional' or'classical hallucinogens' including DMT, Psilocybin, LSD.'A hallucinogen' in this sense broadly refers to any substance which causes changes in perception or hallucinations, while psychedelics carry a positive connotation of general perceptual enhancement. In contrast to Hollister's original criteria, adverse effects may predominate with some hallucinogens with this application of the term; the word psychedelic was coined to express the idea of a drug that makes manifest a hidden but real aspect of the mind. It is applied to any drug with perception-altering effects such as LSD and other ergotamine derivatives, DMT and other tryptamines including the alkaloids of Psilocybe spp. mescaline and other phenethylamines. The term "psychedelic" is applied somewhat interchangeably with "psychotomimetic" and "hallucinogen", The classical hallucinogens are considered to be the representative psychedelics and LSD is considered the prototypical psychedelic.
In order to refer to the LSD-like psychedelics, scientific authors have used the term "classical hallucinogen" in the sense defined by Glennon: "The classical hallucinogens are agents that meet Hollister's original definition, but are agents that: bind at 5-HT2 serotonin receptors, are recognized by animals trained to discriminate 1--2-aminopropane from vehicle. Otherwise, when the term "psychedelic" is used to refer only to the LSD-like psychedelics, authors explicitly point that they intend "psychedelic" to be understood according to this more restrictive interpretation. One explanatory model for the experiences provoked by psychedelics is the "reducing valve" concept, first articulated in Aldous Huxley's book The Doors of Perception. In this view, the drugs disable the brain's "filtering" ability to selectively prevent certain perceptions, emotions and thoughts from reaching the conscious mind; this effect has been described as mind expanding, or consciousness expanding, for the drug "expands" the realm of experience available to conscious awareness.
While possessing a unique mechanism of action, cannabis or marijuana has been regarded alongside the classic psychedelics. A designer drug is a structural or functional analog of a controlled substance, designed to mimic the pharmacological effects of the original drug while at the same time avoid being classified as illegal and/or avoid detection in standard drug tests. Many designer drugs and research chemicals are hallucinogenic in nature, such as those in the 2C and 25-NB families. Dissociatives produce analgesia and catalepsy at anesthetic doses, they produce a sense of detachment from the surrounding environment, hence "the state has been designated as dissociative anesthesia since the patient seems disassociated from his environment." Dissociative symptoms include the disruption or compartmentalization of "...the integrated functions of consciousness, identity or perception."p. 523 Dissociation of sensory input can cause derealization, the perception of the outside world as being dream-like or unreal.
Other dissociative experiences include depersonalization, which includes feeling detached from one's body. Simeon offered "...common descriptions of depersonalisation experiences: watching oneself from a distance. However, dissociation is remarkably administered by salvinorin A's potent κ-opioid receptor agonism, though sometimes described as an atypical psychedelic; some dissociatives can have CNS depressant effects, thereby carrying similar risks as opioids, which can slow breathing or heart rate to levels resulting in death (w
Diethyl ether
Diethyl ether, or ether, is an organic compound in the ether class with the formula 2O, sometimes abbreviated as Et2O. It is a colorless volatile flammable liquid, it is used as a solvent in laboratories and as a starting fluid for some engines. It was used as a general anesthetic, until non-flammable drugs were developed, such as halothane, it has been used as a recreational drug to cause intoxication. Most diethyl ether is produced as a byproduct of the vapor-phase hydration of ethylene to make ethanol; this process uses solid-supported phosphoric acid catalysts and can be adjusted to make more ether if the need arises. Vapor-phase dehydration of ethanol over some alumina catalysts can give diethyl ether yields of up to 95%. Diethyl ether can be prepared both in laboratories and on an industrial scale by the acid ether synthesis. Ethanol is mixed with a strong acid sulfuric acid, H2SO4; the acid dissociates in the aqueous environment producing hydronium ions, H3O+. A hydrogen ion protonates the electronegative oxygen atom of the ethanol, giving the ethanol molecule a positive charge: CH3CH2OH + H3O+ → CH3CH2OH2+ + H2OA nucleophilic oxygen atom of unprotonated ethanol displaces a water molecule from the protonated ethanol molecule, producing water, a hydrogen ion and diethyl ether.
CH3CH2OH2+ + CH3CH2OH → H2O + H+ + CH3CH2OCH2CH3This reaction must be carried out at temperatures lower than 150 °C in order to ensure that an elimination product is not a product of the reaction. At higher temperatures, ethanol will dehydrate to form ethylene; the reaction to make diethyl ether is reversible, so an equilibrium between reactants and products is achieved. Getting a good yield of ether requires that ether be distilled out of the reaction mixture before it reverts to ethanol, taking advantage of Le Chatelier's principle. Another reaction that can be used for the preparation of ethers is the Williamson ether synthesis, in which an alkoxide performs a nucleophilic substitution upon an alkyl halide, it is important as a solvent in the production of cellulose plastics such as cellulose acetate. Diethyl ether has a high cetane number of 85–96 and is used as a starting fluid, in combination with petroleum distillates for gasoline and Diesel engines because of its high volatility and low flash point.
Ether starting fluid is sold and used in countries with cold climates, as it can help with cold starting an engine at sub-zero temperatures. For the same reason it is used as a component of the fuel mixture for carbureted compression ignition model engines. In this way diethyl ether is similar to one of its precursors, ethanol. Diethyl ether is a common laboratory aprotic solvent, it has limited solubility in water and dissolves 1.5 g/100 g water at 25 °C. This, coupled with its high volatility, makes it ideal for use as the non-polar solvent in liquid-liquid extraction; when used with an aqueous solution, the diethyl ether layer is on top as it has a lower density than the water. It is a common solvent for the Grignard reaction in addition to other reactions involving organometallic reagents. Due to its application in the manufacturing of illicit substances, it is listed in the Table II precursor under the United Nations Convention Against Illicit Traffic in Narcotic Drugs and Psychotropic Substances as well as substances such as acetone and sulfuric acid.
William T. G. Morton participated in a public demonstration of ether anesthesia on October 16, 1846 at the Ether Dome in Boston, Massachusetts. However, Crawford Williamson Long, is now known to have demonstrated its use as a general anesthetic in surgery to officials in Georgia, as early as March 30, 1842, Long publicly demonstrated ether's use as a surgical anesthetic on six occasions before the Boston demonstration. British doctors were aware of the anesthetic properties of ether as early as 1840 where it was prescribed in conjunction with opium. Diethyl ether supplanted the use of chloroform as a general anesthetic due to ether's more favorable therapeutic index, that is, a greater difference between an effective dose and a toxic dose. Diethyl ether increases tracheobronchial secretions. Diethyl ether could be mixed with other anesthetic agents such as chloroform to make C. E. mixture, or chloroform and alcohol to make A. C. E. Mixture. In the 21st century, ether is used; the use of flammable ether was displaced by nonflammable fluorinated hydrocarbon anesthetics.
Halothane was the first such anesthetic developed and other used inhaled anesthetics, such as isoflurane and sevoflurane, are halogenated ethers. Diethyl ether was found to have undesirable side effects, such as post-anesthetic nausea and vomiting. Modern anesthetic agents reduce these side effects. Prior to 2005 it was on the World Health Organization's List of Essential Medicines for use as an anesthetic. Ether was once used in pharmaceutical formulations. A mixture of alcohol and ether, one part of diethyl ether and three parts of ethanol, was known as "Spirit of ether", Hoffman's Anodyne or Hoffman's Drops. In the United States this concoction was removed from the Pharmacopeia at some point prior to June 1917, as a study published by William Procter, Jr. in the American Journal of Pharmacy as early as 1852 showed that there were differences in formulation to be found between commercial manufacturers, between international pharmacopoeia, from Hoffman's original recipe. The anesthetic and intoxicating effects of ether have made it a recreational drug.
Diethyl ether in anesthetic dosage is an inhalant which has a long history
Opioid
Opioids are substances that act on opioid receptors to produce morphine-like effects. Medically they are used for pain relief, including anesthesia. Other medical uses include suppression of diarrhea, replacement therapy for opioid use disorder, reversing opioid overdose, suppressing cough, suppressing opioid induced constipation, as well as for executions in the United States. Potent opioids such as carfentanil are only approved for veterinary use. Opioids are frequently used non-medically for their euphoric effects or to prevent withdrawal. Side effects of opioids may include itchiness, nausea, respiratory depression and euphoria. Tolerance and dependence will develop with continuous use, requiring increasing doses and leading to a withdrawal syndrome upon abrupt discontinuation; the euphoria attracts recreational use and frequent, escalating recreational use of opioids results in addiction. An overdose or concurrent use with other depressant drugs results in death from respiratory depression.
Opioids act by binding to opioid receptors, which are found principally in the central and peripheral nervous system and the gastrointestinal tract. These receptors mediate the somatic effects of opioids. Opioid drugs include partial agonists, like the anti-diarrhea drug loperamide and antagonists like naloxegol for opioid-induced constipation, which do not cross the blood-brain barrier, but can displace other opioids from binding to those receptors; because opioids are addictive and may result in fatal overdose, most are controlled substances. In 2013, between 28 and 38 million people used opioids illicitly. In 2011, an estimated 4 million people in the United States used opioids recreationally or were dependent on them; as of 2015, increased rates of recreational use and addiction are attributed to over-prescription of opioid medications and inexpensive illicit heroin. Conversely, fears about over-prescribing, exaggerated side effects and addiction from opioids are blamed for under-treatment of pain.
Opioids include opiates, an older term that refers to such drugs derived from opium, including morphine itself. Other opioids are semi-synthetic and synthetic drugs such as hydrocodone and fentanyl; the terms opiate and narcotic are sometimes encountered as synonyms for opioid. Opiate is properly limited to the natural alkaloids found in the resin of the opium poppy although some include semi-synthetic derivatives. Narcotic, derived from words meaning'numbness' or'sleep', as an American legal term, refers to cocaine and opioids, their source materials. In some jurisdictions all controlled drugs are classified as narcotics; the term can have pejorative connotations and its use is discouraged where, the case. The weak opioid codeine, in low doses and combined with one or more other drugs, is available without a prescription and can be used to treat mild pain. Other opioids are reserved for the relief of moderate to severe pain. Opioids are effective for the treatment of acute pain. For immediate relief of moderate to severe acute pain opioids are the treatment of choice due to their rapid onset and reduced risk of dependence.
However a new report showed a clear risk of prolonged opioid use when opioid analgesics are initiated for an acute pain management following surgery or trauma. They have been found to be important in palliative care to help with the severe, disabling pain that may occur in some terminal conditions such as cancer, degenerative conditions such as rheumatoid arthritis. In many cases opioids are a successful long-term care strategy for those with chronic cancer pain. Guidelines have suggested that the risk of opioids is greater than their benefits when used for most non-cancer chronic conditions including headaches, back pain, fibromyalgia, thus they should be used cautiously in chronic non-cancer pain. If used the benefits and harms should be reassessed at least every three months. In treating chronic pain, opioids are an option to be tried after other less risky pain relievers have been considered, including paracetamol/acetaminophen or NSAIDs like ibuprofen or naproxen; some types of chronic pain, including the pain caused by fibromyalgia or migraine, are preferentially treated with drugs other than opioids.
The efficacy of using opioids to lessen chronic neuropathic pain is uncertain. Opioids are contraindicated as a first-line treatment for headache because they impair alertness, bring risk of dependence, increase the risk that episodic headaches will become chronic. Opioids can cause heightened sensitivity to headache pain; when other treatments fail or are unavailable, opioids may be appropriate for treating headache if the patient can be monitored to prevent the development of chronic headache. Opioids are being used more in the management of non-malignant chronic pain; this practice has now led to a new and growing problem with misuse of opioids. Because of various negative effects the use of opioids for long term management of chronic pain is not indicated unless other less risky pain relievers have been found ineffective. Chronic pain which occurs only periodically, such as that from nerve pain and fibromyalgia is better treated with medications other than opioids. Paracetamol and nonsteroidal anti-inflammatory drugs including ibuprofen and naproxen are considered safer alternatives.
They are used combined with opioids, such as paracetamol co
Psychedelic drug
Psychedelics are a class of drug whose primary action is to trigger psychedelic experiences via serotonin receptor agonism, causing thought and visual/auditory changes, altered state of consciousness. Major psychedelic drugs include mescaline, LSD, DMT. Studies show that psychedelics do not lead to addiction. Studies conducted using psilocybin in a psychotheraputic setting reveal that psychedelic drugs may assist with treating alcohol and nicotine addiction. Differing with other psychoactive drugs, such as stimulants and opioids, psychedelics tend to qualitatively alter ordinary conscious experience. Whereas stimulants cause energized feelings and opioids produce a relaxed euphoric state, the psychedelic experience is compared to non-ordinary forms of consciousness such as trance, yoga, religious ecstasy and near-death experiences. Most psychedelic drugs fall into one of the three families of chemical compounds: tryptamines, phenethylamines, or lysergamides. Although lysergamides are their own group they are a tryptamine.
Many psychedelic drugs are illegal worldwide under the UN conventions excepting use in a religious or research context. Despite these controls, recreational use of psychedelics is common; the term psychedelic is derived from the Greek words ψυχή and δηλείν, hence "soul-manifesting", the implication being that psychedelics can access the soul and develop unused potentials of the human mind. The word was coined in 1956 by British psychiatrist, Humphry Osmond, the spelling loathed by American ethnobotanist, Richard Schultes, but championed by the American psychologist, Timothy Leary. Aldous Huxley had suggested to Humphry Osmond in 1956 his own coinage phanerothyme; the term entheogenic has come into use to denote the use of psychedelic drugs in a religious/spiritual/mystical context. Psychedelics have a long history of traditional use in medicine and religion, for their perceived ability to promote physical and mental healing. In this context, they are known as entheogens. Native American practitioners using mescaline-containing cacti have reported success against alcoholism, Mazatec practitioners use psilocybin mushrooms for divination and healing.
Ayahuasca, which contains the potent psychedelic DMT, is used in Peru and other parts of South America for spiritual and physical healing as well as in religious festivals. Classical or serotonergic psychedelics include LSD, mescaline, DMT; this class of psychedelics includes the classical hallucinogens, including the lysergamides like LSD and LSA, tryptamines like psilocybin and DMT, phenethylamines like mescaline and 2C-B. Many of these psychedelics cause remarkably similar effects, despite their different chemical structure. However, many users report that the three families have subjectively different qualities in the "feel" of the experience, which are difficult to describe. At lower doses, these include sensory alterations, such as the warping of surfaces, shape suggestibility, color variations. Users report intense colors that they have not experienced, repetitive geometric shapes are common. Higher doses cause intense and fundamental alterations of sensory perception, such as synesthesia or the experience of additional spatial or temporal dimensions.
Some compounds, such as 2C-B, have tight "dose curves", meaning the difference between a non-event and an overwhelming disconnection from reality can be slight. There can be substantial differences between the drugs, however. For instance, 5-MeO-DMT produces the visual effects typical of other psychedelics and ibogaine is an NMDA receptor antagonist and κ-opioid receptor agonist in addition to being an agonist for the 5-HT2A receptors, resulting in dissociative effects as well. Research published in journal Cell Reports states that psychedelic drugs promote neural plasticity in rats and flies; the empathogen-entactogens are phenethylamines of the MDxx class such as MDMA, MDEA, MDA. Their effects are characterized by feelings of openness, empathy, heightened self-awareness, by mild audio and visual distortions, their adoption by the rave subculture is due to the enhancement of the overall social and musical experience. MDA is atypical to this experience causing hallucinations and psychedelic effects in equal profundity to the chemicals in the 5-HT2A agonist category, but with less mental involvement, is both a serotonin releaser and 5-HT2A receptor agonist.
Certain dissociative drugs acting via NMDA antagonism are known to produce what some might consider psychedelic effects. The main differences between dissociative psychedelics and serotonergic hallucinogens are that the dissociatives cause more intense derealization and depersonalization. For example, ketamine produces sensations of being disconnected from one's body and that the surrounding environment is unreal, as well as perceptual alterations seen with other psychedelics. Salvia divinorum is a dissociative, sometimes classified as an atypical psychedelic; the active molecule in the plant, salvinorin A, is a kappa opioid receptor agonist, working on a part of the brain that de
Nitrous oxide
Nitrous oxide known as laughing gas or nitrous, is a chemical compound, an oxide of nitrogen with the formula N2O. At room temperature, it is a colourless non-flammable gas, with taste. At elevated temperatures, nitrous oxide is a powerful oxidiser similar to molecular oxygen, it is soluble in water. Nitrous oxide has significant medical uses in surgery and dentistry, for its anaesthetic and pain reducing effects, its name "laughing gas", coined by Humphry Davy, is due to the euphoric effects upon inhaling it, a property that has led to its recreational use as a dissociative anaesthetic. It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system, it is used as an oxidiser in rocket propellants, in motor racing to increase the power output of engines. Nitrous oxide occurs in small amounts in the atmosphere, but has been found to be a major scavenger of stratospheric ozone, with an impact comparable to that of CFCs, it is estimated that 30% of the N2O in the atmosphere is the result of human activity, chiefly agriculture.
Nitrous oxide may be used as an oxidiser in a rocket motor. This is advantageous over other oxidisers in that it is much less toxic, due to its stability at room temperature is easier to store and safe to carry on a flight; as a secondary benefit, it may be decomposed to form breathing air. Its high density and low storage pressure enable it to be competitive with stored high-pressure gas systems. In a 1914 patent, American rocket pioneer Robert Goddard suggested nitrous oxide and gasoline as possible propellants for a liquid-fuelled rocket. Nitrous oxide has been the oxidiser of choice in several hybrid rocket designs; the combination of nitrous oxide with hydroxyl-terminated polybutadiene fuel has been used by SpaceShipOne and others. It is notably used in amateur and high power rocketry with various plastics as the fuel. Nitrous oxide may be used in a monopropellant rocket. In the presence of a heated catalyst, N2O will decompose exothermically into nitrogen and oxygen, at a temperature of 1,070 °F.
Because of the large heat release, the catalytic action becomes secondary, as thermal autodecomposition becomes dominant. In a vacuum thruster, this may provide a monopropellant specific impulse of as much as 180 s. While noticeably less than the Isp available from hydrazine thrusters, the decreased toxicity makes nitrous oxide an option worth investigating. Nitrous oxide is said to deflagrate at 600 °C at a pressure of 309 psi. At 600 psi, for example, the required ignition energy is only 6 joules, whereas N2O at 130 psi a 2,500-joule ignition energy input is insufficient. In vehicle racing, nitrous oxide allows the engine to burn more fuel by providing more oxygen than air alone, resulting in a more powerful combustion; the gas is not flammable at a low pressure/temperature, but it delivers more oxygen than atmospheric air by breaking down at elevated temperatures. Therefore, it is mixed with another fuel, easier to deflagrate. Nitrous oxide is a strong oxidant equivalent to hydrogen peroxide, much stronger than oxygen gas.
Nitrous oxide is stored as a compressed liquid. Sometimes nitrous oxide is injected into the intake manifold, whereas other systems directly inject, right before the cylinder to increase power; the technique was used during World War II by Luftwaffe aircraft with the GM-1 system to boost the power output of aircraft engines. Meant to provide the Luftwaffe standard aircraft with superior high-altitude performance, technological considerations limited its use to high altitudes. Accordingly, it was only used by specialised planes such as high-altitude reconnaissance aircraft, high-speed bombers and high-altitude interceptor aircraft, it sometimes could be found on Luftwaffe aircraft fitted with another engine-boost system, MW 50, a form of water injection for aviation engines that used methanol for its boost capabilities. One of the major problems of using nitrous oxide in a reciprocating engine is that it can produce enough power to damage or destroy the engine. Large power increases are possible, if the mechanical structure of the engine is not properly reinforced, the engine may be damaged, or destroyed, during this kind of operation.
It is important with nitrous oxide augmentation of petrol engines to maintain proper operating temperatures and fuel levels to prevent "pre-ignition", or "detonation". Most problems that are associated with nitrous oxide do not come from mechanical failure due to the power increases. Since nitrous oxide allows a much denser charge into the cylinder, it increases cylinder pressures; the increased pressure and temperature can cause problems such as melting valves. It may crack or warp the piston or head and cause pre-ignition due to uneven heating. Automotive-grade liquid nitrous oxide differs from medical-grade nitrous oxide. A small amount of sulfur dioxide is added to prevent substance abuse. Multiple washes through a base can remove this, decreasing the corrosive properties observed when SO2 is further oxidised during combustion into sulfuric
Analgesic
An analgesic or painkiller is any member of the group of drugs used to achieve analgesia, relief from pain. Analgesic drugs act in various ways on the central nervous systems, they are distinct from anesthetics, which temporarily affect, in some instances eliminate, sensation. Analgesics include paracetamol, the nonsteroidal anti-inflammatory drugs such as the salicylates, opioid drugs such as morphine and oxycodone; when choosing analgesics, the severity and response to other medication determines the choice of agent. Analgesic choice is determined by the type of pain: For neuropathic pain, traditional analgesics are less effective, there is benefit from classes of drugs that are not considered analgesics, such as tricyclic antidepressants and anticonvulsants. Topical nonsteroidal anti-inflammatory drugs provided pain relief in common conditions such as muscle sprains and overuse injuries. Since the side effects are lesser, topical preparations could be preferred over oral medications in these conditions.
Each different type of analgesic has its own associated side effects. Analgesics are classified based on their mechanism of action. Paracetamol known as acetaminophen or APAP, is a medication used to treat pain and fever, it is used for mild to moderate pain. In combination with opioid pain medication, paracetamol is now used for more severe pain such as cancer pain and after surgery, it is used either by mouth or rectally but is available intravenously. Effects last between four hours. Paracetamol is classified as a mild analgesic. Paracetamol is safe at recommended doses. Nonsteroidal anti-inflammatory drugs, are a drug class that groups together drugs that decrease pain and lower fever, and, in higher doses decrease inflammation; the most prominent members of this group of drugs, aspirin and naproxen, are all available over the counter in most countries. These drugs have been derived from NSAIDs; the cyclooxygenase enzyme inhibited by NSAIDs was discovered to have at least 2 different versions: COX1 and COX2.
Research suggested most of the adverse effects of NSAIDs to be mediated by blocking the COX1 enzyme, with the analgesic effects being mediated by the COX2 enzyme. Thus, the COX2 inhibitors were developed to inhibit only the COX2 enzyme; these drugs are effective analgesics when compared with NSAIDs, but cause less gastrointestinal hemorrhage in particular. After widespread adoption of the COX-2 inhibitors, it was discovered that most of the drugs in this class increase the risk of cardiovascular events by 40% on average; this led to the withdrawal of rofecoxib and valdecoxib, warnings on others. Etoricoxib seems safe, with the risk of thrombotic events similar to that of non-coxib NSAID diclofenac. Morphine, the archetypal opioid, other opioids all exert a similar influence on the cerebral opioid receptor system. Buprenorphine is a partial agonist of the μ-opioid receptor, tramadol is a serotonin norepinephrine reuptake inhibitor with weak μ-opioid receptor agonist properties. Tramadol is structurally closer to venlafaxine than to codeine and delivers analgesia by not only delivering "opioid-like" effects but by acting as a weak but fast-acting serotonin releasing agent and norepinephrine reuptake inhibitor.
Tapentadol, with some structural similarities to tramadol, presents what is believed to be a novel drug working through two different modes of action in the fashion of both a traditional opioid and as an SNRI. The effects of serotonin and norepinephrine on pain, while not understood, have had causal links established and drugs in the SNRI class are used in conjunction with opioids with greater success in pain relief. Dosing of all opioids may be limited by opioid toxicity, but opioid-tolerant individuals have higher dose ceilings than patients without tolerance. Opioids, while effective analgesics, may have some unpleasant side-effects. Patients starting morphine may experience vomiting. Pruritus may require switching to a different opioid. Constipation occurs in all patients on opioids, laxatives are co-prescribed; when used appropriately and other central analgesics are safe and effective, risks such as addiction and the body's becoming used to the drug can occur. The effect of tolerance means.
When safe to do so, the dosage may need to be increased to maintain effectiveness against tolerance, which may be of particular concern regarding patients suffering with chronic pain and requiring an analgesic over long periods. Opioid tolerance is addressed with opioid rotation therapy in which a patient is switched between two or more non-cross-tolerant opioid medications in order to prevent exceeding safe dosages in the attempt to achieve an adequate analgesic effect. Opioid tolerance should not be confused with opioid-induced hyperalgesia; the symptoms of these two conditions can appear similar but the mechanism of acti
Media related to Dissociatives at Wikimedia Commons